Use of Primary Macrophages for Searching Novel Immunocorrectors

Author(s): Nikita G. Nikiforov, Natalia V. Elizova, Michael Bukrinsky, Larisa Dubrovsky, Vsevolod J. Makeev, Yoshiyuki Wakabayashi, Poching Liu, Kathy K. Foxx, Howard S. Kruth, Xueting Jin, Emile R. Zakiev, Alexander N. Orekhov

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 6 , 2017

Become EABM
Become Reviewer
Call for Editor


In this mini-review, the role of macrophage phenotypes in atherogenesis is considered. Recent studies on distribution of M1 and M2 macrophages in different types of atherosclerotic lesions indicate that macrophages exhibit a high degree of plasticity of phenotype in response to various conditions in microenvironment. The effect of the accumulation of cholesterol, a key event in atherogenesis, on the macrophage phenotype is also discussed. The article presents the results of transcriptome analysis of cholesterol-loaded macrophages revealing genes involved in immune response whose expression rate has changed the most. It turned out that the interaction of macrophages with modified LDL leads to higher expression levels of pro-inflammatory marker TNF-α and antiinflammatory marker CCL18. Phenotypic profile of macrophage activation could be a good target for testing of novel anti-atherogenic immunocorrectors. A number of anti-atherogenic drugs were tested as potential immunocorrectors using primary macrophage-based model.

Keywords: Atherosclerosis, macrophages, phenotype, transcriptome, activation, modified LDL, immunocorrectors, macrophage-based test.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 26 March, 2017
Page: [915 - 920]
Pages: 6
DOI: 10.2174/1381612823666170125110128
Price: $65

Article Metrics

PDF: 26